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Abstract
Background: Patients with non-alcoholic fatty liver diseases (NAFLD) are recommended to have periodic follow-up
exams because these patients are at increased risk of the presence of non-alcoholic steatohepatitis (NASH), which
can lead to cirrhosis or hepatocellular carcinoma. We investigated the follow-up status of NAFLD patients after a
liver biopsy examination.
Methods: We compared the follow-up rates of NAFLD patients who had received an ultrasonography-guided liver
biopsy and patients who had received a liver biopsy for chronic viral hepatitis (hepatitis B or C).
Results: The 1- and 3-year follow-up rates after the liver biopsy were 92.7% and 88.3% for patients with chronic
HBV infection, and 93.4% and 88.2% for patients with chronic HCV infection, respectively. In contrast, the follow-up
rates for NAFLD patients were 77.6% and 49.9%, respectively, which were significantly lower than those of patients
with chronic viral hepatitis (p < 0.0001). Among NAFLD patients, the respective 1- and 3-year follow-up rates were
73.0% and 44.6% for patients with simple steatosis and 80.0% and 52.4% for patients with NASH based on a
pathologic diagnosis, without significant difference between these two subgroups (p = 0.5202).
Conclusions: The outpatient-based follow-up rate after a liver biopsy was significantly lower in NAFLD patients
compared to patients with chronic viral hepatitis, regardless of the presence of NASH. It is important to determine
how to maintain regular hospital visits for NAFLD patients, preventing patient attrition.
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Background
Nonalcoholic fatty liver disease (NAFLD) encompasses a
histological spectrum that ranges from simple steatosis
to nonalcoholic steatohepatitis (NASH), which can pro-
gress to cirrhosis and end-stage liver disease. NAFLD is
one of the most common liver diseases in both Western
and Asian countries [1-5], affecting 30% of the general
Western adult population [6].
Because NAFLD includes patients with NASH that
can progress to cirrhosis [1,7,8] and because it is still
controversial whether simple steatosis converts to
NASH, it is important to carefully monitor NAFLD
patients at regular follow-up exams. Furthermore, in the
absence of treatment modalities with proven efficacy,
outpatient-based weight management is currently an
important treatment for NAFLD patients. However, it is
unclear whether NAFLD patients have a sufficient
understanding of the importance of periodic follow-up
visits compared to patients with viral hepatitis or other
liver diseases. Whereas the follow-up rate of patients
with chronic viral hepatitis (chronic hepatitis B or C) is
high in Japan, the follow-up rate of patients with
NAFLD, in comparison to patients with viral hepatitis,
is not clarified.
In the present study, we investigated the follow-up
status of NAFLD patients, including patients with both
simple steatosis and NASH, after the disease diagnosis
was histologically confirmed by a liver biopsy.
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Patients and Follow-up Visits
A total of 610 patients had undergone an ultrasonogra-
phy-guided liver biopsy examination at our institution to
confirm a diagnosis of liver diseases during a 5-year per-
iod between April 2003 and March 2008. These patients
received a liver biopsy to evaluate of the grade of liver
damage (activity of hepatitis), examine the degree of liver
fibrosis, and investigate or confirm the diagnosis. The
patients included 305 males and 305 females with a mean
age of 53.9 ± 12.7 years. All patients underwent an ultra-
sonography-guided fine needle liver biopsy using a 17 G
biopsy needle during their 3 to 4 days of hospitalization.
Among these patients, 69 patients had chronic hepatitis
B virus (HBV) infection, 354 patients had chronic hepati-
tis C virus (HCV) infection, and 135 patients had NAFLD
by clinical evaluation. We analyzed the follow-up rates of
these patient groups after liver biopsy.
The patients were informed of the pathologic results of
t h eb i o p s yw h e nt h e yv i s i t e dt h eo u t p a t i e n tc l i n i c2o r3
weeks after the biopsy. Patients with chronic viral hepati-
tis (hepatitis B or C) were advised to receive regular peri-
odic follow-up exams every 3 to 6 months to monitor
liver damage, fibrosis, and the development of HCC.
Patients who were diagnosed with NASH were informed
that they could potentially progress to cirrhosis and were
at increased risk of developing hepatocellular carcinoma
(HCC). They were also advised to have regular follow-up
visits at our institution every 3 to 6 months. Patients who
were diagnosed with simple steatosis were informed that
it has not been fully determined if simple steatosis is con-
verts to NASH and were advised to have regular follow-
up exams at our institution every 6 months.
Our institution provides appointment-based outpatient
care, and most patients who visit the clinic reserve the
next available appointment. If a patient did not visit the
clinic despite a scheduled appointment, the patient was tel-
ephoned, advised to maintain their regular visits, and given
a new appointment. This telephone contact was repeated
at least three times. Patients were routinely monitored
from the biopsy date until the end of December 2010.
The study protocol was in compliance with the Hel-
sinki Declaration and was approved by the institutional
review board of the Ogaki Municipal Hospital for the
review of patient clinical records. Written informed con-
sent was obtained from patients who continued to be
followed up.
Clinical and Pathologic Diagnosis of Non-alcoholic Fatty
Liver Diseases, Simple Steatosis, and Non-alcoholic
Steatohepatitis
A patient was clinically diagnosed with a fatty liver before
receiving a biopsy if they met made when the following
criteria: 1) persistently abnormal liver function tests for
more than 3 months, 2) ultrasonographic images showing
steatosis, 3) no evidence of alcohol abuse, and 4) exclusion
of other liver diseases and other known causes of steatosis
based on the results of specific clinical, biochemical, or
imaging studies. The ultrasonographic findings of steatosis
were based on known criteria that are used to diagnose a
fatty liver by ultrasonography (hepatorenal echo contrast,
liver brightness, deep attenuation, and vascular blurring).
The first two factors were used as definitive criteria, while
the last two factors were taken into account as needed.
NAFLD was pathologically diagnosed based on pathologic
findings in the biopsied liver specimens. The liver biopsy
specimens were stained with hematoxylin/eosin, Masson’s
trichrome, and PAS and then examined by experienced
pathologists. A liver with steatosis involving at least 10%
of the hepatocytes was considered to have NAFLD. The
presence of NASH was defined according to the NAFLD
activity score (NAS) as proposed by the Center for Neu-
roscience Research and National Institutes of Health [9].
Statistical Analyses
Quantitative values are reported as the mean ± SD.
Between-group differences were analyzed by the chi-
square test. Differences in quantitative values between
two groups were analyzed by the Mann-Whitney U test.
Follow-up rates were analyzed using the Kaplan-Meier
method, and the log-rank test was used to compare the
follow-up rates. The date of liver biopsy was defined as
time zero when calculating the patient follow-up rates.
Patients who continued their follow-up schedule were
censored. Patients who missed a follow-up visit were
not censored. All p-values were two-tailed, and p <0 . 0 5
was considered statistically significant.
Results
Patient Characteristics
Table 1 shows the clinical characteristics of the patients
who underwent a liver biopsy. Patients with chronic
HCV infection were significantly older than patients
with chronic HBV infection or NAFLD patients (both, p
< 0.0001). The prevalence of females was significantly
higher among patients with chronic HCV infection com-
pared to NAFLD patients (p =0 . 0 0 9 4 ) .T h es e r u mA L T
activity was significantly higher in NAFLD patients than
in patients chronically infected with HCV (p < 0.0001).
In contrast, there were no differences in the serum ALT
activity between patients with NAFLD and those with
chronic HBV infection (p = 0.4773).
Follow-up Status after the Liver Biopsy
The follow-up rates of patients after the liver biopsy are
shown in Figure 1 according to the underlying liver
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biopsy were 92.7% and 88.3% for patients with chronic
HBV infection, 93.4% and 88.2% for patients with
chronic HCV infection, and 77.6% and 49.9% for
NAFLD patients, respectively. There were no differences
in the follow-up rates between patients with chronic
HBV infection and those with chronic HCV infection (p
= 0.7299). By contrast, the post-liver biopsy follow-up
rate was significantly lower in NAFLD patients com-
pared to those with HBV infection or HCV infection
(both, p < 0.0001); more than 50% of patients discontin-
ued their follow-up exams within 3 years after the liver
biopsy. When we compared the post-liver biopsy follow-
up rates between patients with chronic HCV infection
and those with NAFLD focusing on patients who had
not been administered medication, the follow-up rate of
patients with NAFLD was significantly lower than that
of patients with HCV (p < 0.0001, Figure 2). In addition,
when we compared the follow-up rates between NAFLD
patients and patients who had been chronically infected
with HCV but were successfully treated with an antiviral
therapy with interferon/peginterferon with or without
ribavirin (sustained virologic responders), NAFLD
patients had a significantly lower follow-up rate (p <
0.0001, Figure 3).
Comparison of Characteristics Between Non-alcoholic
Fatty Liver Disease Patients Who Continued and
Discontinued Their Follow-up Exams
When the background characteristics were compared
between NAFLD patients who continued and discontin-
ued their periodic follow-up visit (Table 2), the patients
who discontinued their follow-up visit were significantly
younger than those who continued their regular follow-
up exams. The prevalence of NASH and simple steatosis
by pathologic evaluation did not differ between patients
who had continued and discontinued their follow-up
exams. Also, the percentage of patients who had been
administered medication did not differ between patients
who continued and discontinued their follow-up visit.
Figure 4 compares the follow-up rates after the liver
biopsy between patients with NASH and those with sim-
ple steatosis. The 1- and 3-year follow-up rates were
Table 1 Clinical characteristics of patients who received a
liver biopsy.
NAFLD
(n = 135)
Chronic
HBV infection
(n = 69)
Chronic
HCV infection
(n = 354)
Age
(years: mean ± S.
D.)
48.8 ± 14.7 47.1 ± 12.3 56.5 ± 11.0
Sex
(male/female) (%)
84(62.2)/51
(37.8)
40(58.0)/29
(42.0)
172(48.6)/182
(51.4)
AST
(IU/L: mean ± S.D.)
58.0 ± 42.6 78.2 ± 67.4 55.9 ± 45.4
ALT
(IU/L: mean ± S.D.)
94.7 ± 67.8 126.3 ± 119.6 70.9 ± 74.1
NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B virus; HCV, hepatitis
C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase
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Figure 1 Post-liver biopsy follow-up rates of patients according
to the underlying liver disease. The follow-up rate was
significantly lower in patients with nonalcoholic fatty liver disease
than in patients with chronic hepatitis B or C virus infection (both, p
< 0.0001). There was no difference in the follow-up rate between
patients with chronic HBV infection and those with chronic HCV
infection (p = 0.7299).
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Figure 2 Comparison of the post-biopsy follow-up rates of
patients with chronic hepatitis C virus (HCV) infection and
those with nonalcoholic fatty liver disease (NAFLD), focusing
on patients who had not been administered medication. The
follow-up rate remained significantly lower in patients with NAFLD
than in patients with chronic HCV infection (p < 0.0001).
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Page 3 of 673.0% and 44.6% for patients with simple steatosis and
80.0% and 52.4% for patients with NASH, respectively,
without significant differences between these two groups
(p = 0.5202). The presence of NASH, as determined by
a pathologic diagnosis, did not influence the follow-up
rate after the liver biopsy.
Among 65 patients who discontinued their follow-up
visit for NAFLD, 13 patients (20.0%) had received peri-
odic follow-up examinations for diabetes at the diabetes
department of our institution, and 15 patients (23.1%)
had received follow-up exams for diabetes by their
family physician. However, in both cases, the patients
were not examined for liver disease.
Discussion
Regular outpatient follow-up visits are important for
patients with chronic liver diseases. In particular, pre-
vious studies have shown that periodic HCC surveillance
in patients with liver diseases improves the patient sur-
vival due to the detection of early-stage HCC [10,11]. In
addition, it is important for NAFLD patients to receive
regular advice and be monitored for weight loss, exer-
cise, and specific diets at outpatient clinics to prevent
the conversion from simple steatosis to NASH and the
progression of NASH. However, there is no study that
investigated the outpatient follow-up of patients with
NAFLD.
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Figure 3 Comparison of the post-liver biopsy follow-up rates
in patients with nonalcoholic fatty liver disease (NAFLD) and
patients who had been successfully treated for hepatitis C
virus (HCV) with antiviral therapy (sustained virologic
responders). The follow-up rate was significantly lower in NAFLD
patients than in sustained virologic responders for HCV (p < 0.0001).
Table 2 Comparison of the characteristics of non-alcoholic fatty liver disease patients who continued and
discontinued their follow-up exams after a liver biopsy.
Patients who maintained
their follow-up exams
(n = 68)
Patients who discontinued
their follow-up exams
(n = 67)
p-value
Age
(years: mean ± S.D.)
52.6 ± 13.4 44.9 ± 15.2 0.0035
Sex
(male/female) (%)
42 (61.8)/26 (38.2) 42 (62.7)/25 (37.3) 0.9120
AST
(IU/L: mean ± S.D.)
59.6 ± 35.0 56.4 ± 49.4 0.1208
ALT
(IU/L: mean ± S.D.)
93.6 ± 70.5 95.9 ± 65.4 0.5928
Medication
(yes/no) (%)
21 (30.9)/47 (69.4) 18 (26.9)/49 (73.1) 0.7442
Pathologic diagnosis
(NASH/simple steatosis) (%)
47 (69.1)/21 (30.9) 43 (64.2)/24 (35.8) 0.6691
AST, aspartate aminotransferase; ALT, alanine aminotransferase; NASH: non-alcohol steatohepatitis.
Simple steatosis (n=45)
Non-alcoholic steatohepatitis (n=90)
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Figure 4 Comparison of the post-biopsy follow-up rates of
patients with nonalcoholic fatty liver disease between patients
with nonalcoholic steatohepatitis and those with simple
steatosis. There were no differences in the follow-up rates (p =
0.5202).
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patients have a markedly reduced follow-up rate after
they receive their initial diagnostic liver biopsy, in com-
parison to those with viral hepatitis. The follow-up rate
of NAFLD patients was significantly lower than that of
patients with chronic HCV infection, even when focus-
ing on patients who had not been administered medica-
tion. In addition, the post-biopsy follow-up rate of
NAFLD patients was lower in comparison to patients
whose chronic HCV infection in was eradicated with
antiviral therapy, in whom the follow-up rate was lower
compared to patients with ongoing HCV infection [12].
In a previous study on patients with alcoholic liver dis-
ease, Trabut et al. reported that a liver biopsy did not
further motivate patients to abstain from alcohol [13].
Similarly, in these findings, a liver biopsy did not moti-
vate patients to attend follow-up visits that were
designed to control and monitor NAFLD.
When we compared NAFLD patients who continued
and discontinued their follow-up visits, there was a signifi-
cant difference in age between these two subgroups, and
younger patients were more likely to miss subsequent fol-
low-up exams. This could be partially due to the difficulty
in visiting the hospital due to the limited appointment
times, and partly because younger patients tend to be less
interested in their health than older patients. Interestingly,
there were no differences in the follow-up rates between
patients with and without NASH. The presence of NASH
did not influence the follow-up rate of NAFLD patients,
despite the fact that these patients were told that they
were at increased risk of developing cirrhosis or HCC.
This could be partly because NAFLD patients often do not
have accurate and detailed knowledge on the natural
course of NASH and the potential occurrence of HCC.
The increased awareness of the risk of HCC in patients
with chronic viral hepatitis has been established in Japan
and could have increased the number of patients under
surveillance. However, the present study indicates that
patients in Japan are insufficiently aware that they are at
increased risk of NASH progressing to cirrhosis or devel-
oping HCC. Also, we observed the similar percentage of
patients who had been administered medication between
patients who continued and discontinued regular follow-
up visit. Therefore, the administration of medication did
not prevent the drop out from regular visit in NAFLD
patients. The medication that had been administered for
NAFLD patients included ursodeoxycolic acid, or drugs
for diabetes, hypertension, or hyperlipidemia, and was not
drugs for NAFLD in the absence of definitive drugs for
NAFLD. The emergence of drugs for NASH or NAFLD
may increase the follow-up rate of patients with NAFLD
in the future.
There are several limitations on this study. This is a ret-
rospective study on the basis of the reviews of medical
record. In addition, this is a study conducted in one region
of Japan. All people in Japan are usually covered by a
national medical insurance system, and the follow-up rates
of patients with chronic hepatitis virus infection are very
high. Therefore, the results observed in this study will not
be applicable in other countries with a different medical
insurance system or with different prevalence of patients
with NAFLD and those with viral hepatitis.
Conclusions
NAFLD patients had a low post-liver biopsy follow-up
rate. Thus, it is important to continue the current
efforts to inform individuals in Japan of the risks of this
disease. Furthermore, given the large number of NAFLD
patients, it will be important to further examine meth-
ods to identify patients with NAFLD who are at higher
risk for disease progression or are at risk for developing
HCC [14,15]. For patients chronically infected with
HBV or HCV, chronic hepatitis virus infection is a risk
factor for progression to cirrhosis or development of
HCC. In contrast, it is not easy to identify NAFLD
patients who are at high risk for progressing to cirrhosis
or developing HCC. It will be necessary to further iden-
tify patients who are at increased risk for progressing to
cirrhosis or developing HCC, even among patients who
are pathologically confirmed to have NASH, in order to
further clarify and better monitor patients with NASH
who are at higher risk for disease progression and HCC,
identifying patients who we should be strongly advised
to have regular follow-up exams.
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